Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.
aortic valve stenosis
diabetes mellitus, type 2
magnetic resonance imaging
myocardial blood flow
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
10 10 2023
10 10 2023
Historique:
medline:
11
10
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
ppublish
Résumé
Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR. Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (mean, 71 years of age [95% CI, 69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing. Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (mean [95% CI]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75]; Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.
Sections du résumé
BACKGROUND
Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR.
METHODS
Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (mean, 71 years of age [95% CI, 69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing.
RESULTS
Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (mean [95% CI]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75];
CONCLUSIONS
Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.
Identifiants
pubmed: 37746744
doi: 10.1161/CIRCULATIONAHA.122.063444
pmc: PMC10558154
doi:
Substances chimiques
Vasodilator Agents
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1153Subventions
Organisme : Wellcome Trust
ID : 221690/Z/20/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 221805/Z/20/Z
Pays : United Kingdom
Références
Diabetes Care. 2022 Aug 1;45(8):1852-1862
pubmed: 35789379
Diabetes. 2018 Jul;67(7):1395-1400
pubmed: 29661781
Circulation. 2020 Jun 16;141(24):1971-1985
pubmed: 32438845
J Am Coll Cardiol. 2016 Jul 5;68(1):53-63
pubmed: 27364051
N Engl J Med. 2007 Mar 15;356(11):1140-51
pubmed: 17360992
JACC Cardiovasc Interv. 2021 Feb 8;14(3):261-274
pubmed: 33541537
Circulation. 1997 Oct 7;96(7):2190-6
pubmed: 9337189
Eur Heart J. 2016 Dec 07;37(46):3461-3469
pubmed: 26392437
N Engl J Med. 2020 Feb 27;382(9):799-809
pubmed: 31995682
Circulation. 2020 Apr 7;141(14):1152-1163
pubmed: 32138541
Radiology. 2001 Jun;219(3):637-43
pubmed: 11376247
Diabetes Obes Metab. 2008 Jun;10 Suppl 1:8-15
pubmed: 18435669
J Cardiovasc Magn Reson. 2014 Nov 20;16:92
pubmed: 25410203
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1404-10
pubmed: 12805026
Circulation. 2012 Oct 9;126(15):1858-68
pubmed: 22919001
Cardiovasc Diabetol. 2018 Oct 16;17(1):135
pubmed: 30326902
Circulation. 2011 Sep 6;124(10):1151-9
pubmed: 21844073
Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174
pubmed: 34964815
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96
pubmed: 34964868
Circulation. 2002 Apr 9;105(14):1727-33
pubmed: 11940554
Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):e62-e84
pubmed: 34739054
Eur Heart J. 2017 Apr 21;38(16):1222-1229
pubmed: 28204448
J Cardiovasc Magn Reson. 2014 Apr 29;16:29
pubmed: 24779370
J Cardiovasc Magn Reson. 2017 Apr 7;19(1):43
pubmed: 28385161
Interact Cardiovasc Thorac Surg. 2020 Dec 7;31(6):796-802
pubmed: 33150396
Circ Heart Fail. 2011 May;4(3):286-92
pubmed: 21357546
Diabetes Care. 2006 Jan;29(1):107-12
pubmed: 16373905
Open Heart. 2017 Apr 13;4(1):e000588
pubmed: 28674629
Circulation. 2018 Oct 30;138(18):1935-1947
pubmed: 30002099
Diabetes Care. 2022 Dec 1;45(12):e176-e178
pubmed: 36194432
Obesity (Silver Spring). 2022 May;30(5):1079-1090
pubmed: 35357083
J Am Heart Assoc. 2021 Jun 15;10(12):e018998
pubmed: 34107742
Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):524
pubmed: 35636831
JACC Cardiovasc Imaging. 2017 Nov;10(11):1320-1333
pubmed: 28017384
Diabetes. 2016 Jan;65(1):44-52
pubmed: 26438611
Ann Thorac Surg. 2010 Jul;90(1):124-30
pubmed: 20609762
Cardiovasc Res. 2009 Feb 15;81(3):412-9
pubmed: 18987051
Ann Thorac Surg. 2014 Nov;98(5):1564-70; discussion 1570-1
pubmed: 25240781
Circ Res. 2020 Mar 13;126(6):725-736
pubmed: 32078413
Int J Cardiovasc Imaging. 2021 Mar;37(3):813-823
pubmed: 33040296
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
JAMA Cardiol. 2018 Nov 1;3(11):1060-1068
pubmed: 30285058
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458
Circulation. 2009 Apr 14;119(14):1918-24
pubmed: 19332463
Diabetes. 2021 Dec;70(12):2810-2822
pubmed: 34610982
Heart. 2022 Oct 28;108(22):1815-1821
pubmed: 35697496